EPISODE · Apr 15, 2021 · 7 MIN
Investigational Drug Provides Improved Quality of Life for PNH Patients
from Rare Disease Discussions · host CheckRare Editors
Cedric Francois, MD, PhD, Co-Founder & CEO of Apellis Pharmaceuticals, discusses the results of the PEGASUS study evaluating the efficacy and safety of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH).Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Embed this episode
NOW PLAYING
Investigational Drug Provides Improved Quality of Life for PNH Patients
No transcript for this episode yet
Similar Episodes
No similar episodes found.